- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Advances in Pharmacological Sciences
Volume 2011 (2011), Article ID 326724, 6 pages
Toxicokinetics of Kava
Faculty of Pharmacy, University of Sydney, Bank Building (A15), Sydney, NSW 2006, Australia
Received 30 November 2010; Accepted 24 January 2011
Academic Editor: Charles P. France
Copyright © 2011 Anthony Rowe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- P. A. Whitton, A. Lau, A. Salisbury, J. Whitehouse, and C. S. Evans, “Kava lactones and the kava-kava controversy,” Phytochemistry, vol. 64, no. 3, pp. 673–679, 2003.
- P. P. Fu, Q. Xia, L. Guo, H. Yu, and P. C. Chan, “Toxicity of kava kava,” Journal of Environmental Science and Health, Part C, vol. 26, no. 1, pp. 89–112, 2008.
- R. Teschke, J. Sarris, and V. Lebot, “Kava hepatotoxicity solution: a six-point plan for new kava standardization,” Phytomedicine, vol. 18, no. 2-3, pp. 96–103, 2011.
- L. D. Dinh, U. Simmen, K. B. Bueter, B. Bueter, K. Lundstrom, and W. Schaffner, “Interaction of various Piper methysticum cultivars with CNS receptors in vitro,” Planta Medica, vol. 67, no. 4, pp. 306–311, 2001.
- N. P. Clayton, K. Yoshizawa, G. E. Kissling, L. T. Burka, P. C. Chan, and A. Nyska, “Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract,” Experimental and Toxicologic Pathology, vol. 58, no. 4, pp. 223–236, 2007.
- L. Zou, G. L. Henderson, M. R. Harkey, Y. Sakai, and A. Li, “Effects of kava (kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes,” Phytomedicine, vol. 11, no. 4, pp. 285–294, 2004.
- P. J. Mulholland and M. A. Prendergast, “Post-insult exposure to () kavain potentiates N-methyl-D-aspartate toxicity in the developing hippocampus,” Brain Research, vol. 945, no. 1, pp. 106–113, 2002.
- J. Tang, R. A. Dunlop, A. Rowe, K. J. Rodgers, and I. Ramzan, “Kavalactones yangonin and methysticin induce apoptosis in human hepatocytes (HepG2) in vitro,” Phytotherapy Research, vol. 25, no. 3, pp. 417–423, 2011.
- F. Tarbah, Y. Barguil, W. Weinmann, et al., “Death after consumption of kava beverage in combination with alcohol and cannabis,” in GTFCh (Society of Toxicological and Forensic Chemistry) Symposium, Mosbach, Germany, 2003.
- K. Dragull, W. Y. Yoshida, and C. S. Tang, “Piperidine alkaloids from Piper methysticum,” Phytochemistry, vol. 63, no. 2, pp. 193–198, 2003.
- P. V. Nerurkar, K. Dragull, and C. S. Tang, “In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones,” Toxicological Sciences, vol. 79, no. 1, pp. 106–111, 2004.
- S. T. S. Lim, K. Dragull, C. S. Tang, H. C. Bittenbender, J. T. Efird, and P. V. Nerurkar, “Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats,” Toxicological Sciences, vol. 97, no. 1, pp. 214–221, 2007.
- M. Lechtenberg, B. Quandt, M. Schmidt, and A. Nahrstedt, “Is the alkaloid pipermethystine connected with the claimed liver toxicity of kava products?” Pharmazie, vol. 63, no. 1, pp. 71–74, 2008.
- J. W. Jhoo, J. P. Freeman, T. M. Heinze et al., “In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum),” Journal of Agricultural and Food Chemistry, vol. 54, no. 8, pp. 3157–3162, 2006.
- T. D. Xuan, M. Fukuta, A. C. Wei, A. A. Elzaawely, T. D. Khanh, and S. Tawata, “Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots,” Journal of Natural Medicines, vol. 62, no. 2, pp. 188–194, 2008.
- P. Zhou, S. Gross, J.-H. Liu et al., “Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-κB and MAPK signaling pathways,” FASEB Journal, vol. 24, no. 12, pp. 4722–4732, 2010.
- “Vanuatu Legislation: Kava Act,” 2002, http://www.paclii.org/databases.html#VU.
- V. Lebot, M. Merlin, and L. Lindstrom, Kava, the Pacific Elixir, Yale University Press, Rochester, Vt, USA, 1997.
- R. Teschke, A. Genthner, and A. Wolff, “Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures,” Journal of Ethnopharmacology, vol. 123, no. 3, pp. 378–384, 2009.
- M. H. Pittler and E. Ernst, “Kava extract for treating anxiety,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003383, 2003.
- S. Witte, D. Loew, and W. Gaus, “Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders,” Phytotherapy Research, vol. 19, no. 3, pp. 183–188, 2005.
- K. M. Connor, J. R. T. Davidson, L. E. Churchill, S. Witte, D. Loew, and W. Gaus, “Adverse-effect profile of kava,” CNS Spectrums, vol. 6, no. 10, pp. 848–853, 2001.
- D. L. Clouatre, “Kava kava: examining new reports of toxicity,” Toxicology Letters, vol. 150, no. 1, pp. 85–96, 2004.
- R. Teschke, A. Schwarzenboeck, and K. H. Hennermann, “Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases,” European Journal of Gastroenterology & Hepatology, vol. 20, no. 12, pp. 1182–1193, 2008.
- R. Teschke, A. Schwarzenboeck, and A. Akinci, “Kava hepatotoxicity: a European view,” New Zealand Medical Journal, vol. 121, no. 1283, pp. 90–98, 2008.
- S. A. Norton and P. Ruze, “Kava dermopathy,” Journal of the American Academy of Dermatology, vol. 31, no. 1, pp. 89–97, 1994.
- C. Ulbricht, E. Basch, H. Boon et al., “Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration,” Expert Opinion on Drug Safety, vol. 4, no. 4, pp. 779–794, 2005.
- I. Ramzan and H. V. Tran, “Chemistry of kava and kavalactones,” in Kava: From Ethnology to Pharmacology (Medicinal and Aromatic Plants—Industrial Profile), Y. N. Singh, Ed., pp. 76–103, CRC Press, Boca Raton, Fla, USA, 2004.
- J. Barnes, L. A. Anderson, and J. D. Phillipson, “Herbal Medicines,” 2007, http://www.medicinescomplete.com/mc/herbals/2008/1000734502.htm#hrb1000756090.
- A. M. Duffield, D. D. Jamieson, R. O. Lidgard, P. H. Duffield, and D. J. Bourne, “Identification of some human urinary metabolites of the intoxicating beverage kava,” Journal of Chromatography A, vol. 475, pp. 273–281, 1989.
- C. Köppel and J. Tenczer, “Mass spectral characterization of urinary metabolites of D,L-kawan,” Journal of Chromatography B, vol. 562, no. 1-2, pp. 207–211, 1991.
- A. K. Rasmussen, R. R. Scheline, E. Solheim, and R. Hansel, “Metabolism of some kava pyrones in the rat,” Xenobiotica, vol. 9, no. 1, pp. 1–16, 1979.
- F. Tarbah, H. Mahler, B. Kardel, W. Weinmann, D. Hafner, and T. Daldrup, “Kinetics of kavain and its metabolites after oral application,” Journal of Chromatography B, vol. 789, no. 1, pp. 115–130, 2003.
- L. Zou, M. R. Harkey, and G. L. Henderson, “Synthesis, in vitro reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestion,” Planta Medica, vol. 71, no. 2, pp. 142–146, 2005.
- B. M. Johnson, S. X. Qiu, S. Zhang et al., “Identification of novel electrophilic metabolites of Piper methysticum Forst. (kava),” Chemical Research in Toxicology, vol. 16, no. 6, pp. 733–740, 2003.
- J. M. Mathews, A. S. Etheridge, J. L. Valentine et al., “Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro,” Drug Metabolism and Disposition, vol. 33, no. 10, pp. 1555–1563, 2005.
- S. Russmann, Y. Barguil, P. Cabalion, M. Kritsanida, D. Duhet, and B. H. Lauterburg, “Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia,” European Journal of Gastroenterology & Hepatology, vol. 15, no. 9, pp. 1033–1036, 2003.
- S. Russmann, B. H. Lauterburg, and A. Helbling, “Kava hepatotoxicity,” Annals of Internal Medicine, vol. 135, no. 1, pp. 68–69, 2001.
- M. Ingelman-Sundberg, “Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity,” Pharmacogenomics Journal, vol. 5, no. 1, pp. 6–13, 2005.
- M. Escher, J. Desmeules, E. Giostra, and G. Mentha, “Hepatitis associated with kava, a herbal remedy for anxiety,” British Medical Journal, vol. 322, no. 7279, p. 139, 2001.
- S. Fu, E. Korkmaz, F. Braet, Q. Ngo, and I. Ramzan, “Influence of kavain on hepatic ultrastructure,” World Journal of Gastroenterology, vol. 14, no. 4, pp. 541–546, 2008.
- A. R. Clough, S. P. Jacups, Z. Wang et al., “Health effects of kava use in an eastern Arnhem Land Aboriginal community,” Internal Medicine Journal, vol. 33, no. 8, pp. 336–340, 2003.
- A. R. Clough, R. S. Bailie, and B. Currie, “Liver function test abnormalities in users of aqueous kava extracts,” Journal of Toxicology. Clinical Toxicology, vol. 41, no. 6, pp. 821–829, 2003.
- A. C. Brown, J. Onopa, P. Holck et al., “Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii,” Clinical Toxicology, vol. 45, no. 5, pp. 549–556, 2007.
- G. Zollner and M. Trauner, “Mechanisms of cholestasis,” Clinics in Liver Disease, vol. 12, no. 1, pp. 1–26, 2008.
- R. A. Roberts, P. E. Ganey, C. Ju, L. M. Kamendulis, I. Rusyn, and J. E. Klaunig, “Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis,” Toxicological Sciences, vol. 96, no. 1, pp. 2–15, 2007.
- G. Kolios, V. Valatas, and E. Kouroumalis, “Role of Kupffer cells in the pathogenesis of liver disease,” World Journal of Gastroenterology, vol. 12, no. 46, pp. 7413–7420, 2006.
- M. D. Wheeler, H. Kono, M. Yin et al., “The role of Kupffer cell oxidant production in early ethanol-induced liver disease,” Free Radical Biology and Medicine, vol. 31, no. 12, pp. 1544–1549, 2001.
- J. Y. Li, X. Gu, W. H. Zhang, S. Jia, and Y. Zhou, “GdCl3 abates hepatic ischemia-reperfusion injury by inhibiting apoptosis in rats,” Hepatobiliary and Pancreatic Diseases International, vol. 8, no. 5, pp. 518–523, 2009.
- D. Henrich, M. Lehnert, C. Herzog et al., “Differential effects of GdCl3 or MDP treatment on rat liver microcirculation and gene expression in the hepatic non-parenchymal cell fraction in LPS shock,” Microcirculation, vol. 15, no. 5, pp. 427–439, 2008.
- E. Sturm, R. Havinga, J. F. W. Baller et al., “Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats,” Journal of Hepatology, vol. 42, no. 1, pp. 102–109, 2005.
- S. S. Du, M. Qiang, Z. C. Zeng et al., “Inactivation of Kupffer cells by gadolinium chloride protects murine liver from radiation-induced apoptosis,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 4, pp. 1225–1234, 2010.
- W. Huang, A. Metlakunta, N. Dedousis et al., “Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance,” Diabetes, vol. 59, no. 2, pp. 347–357, 2010.
- P. Neafsey, G. Ginsberg, D. Hattis, and B. Sonawane, “Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity,” Journal of Toxicology and Environmental Health Part B, vol. 12, no. 5-6, pp. 334–361, 2009.